cebada

Barley (Hordeum vulgare L.): A Comprehensive Reference

1. Identity: Botanical Classification, Natural Source, and Common Forms

Botanical and Chemical Identity

Barley (Hordeum vulgare) stands as an important grain crop among cereal grains for its remarkable nutritional profile. It belongs to family Poaceae and is considered one of the founder crops of old-world agriculture. The genus name Hordeum encompasses both wild and cultivated species; the primary wild ancestor of cultivated barley is Hordeum spontaneum.

Barley is a genetically diverse cereal classified into several types. Based on hull adherence, it is classified as a hull-less type, in which the hull weakly adheres to the grain and naturally separates during harvesting, or a hulled type. According to amylose content, barley is classified as waxy, normal, and high-amylose types, corresponding to 0–5%, 5–35%, and higher than 35% amylose content, respectively. Barley is further classified based on its grain color into yellow, white, blue, black, purple, and green types. Moreover, barley is classified according to other chemical components as high-lysine, high-β-glucan, and proanthocyanidin-free types, and based on growth habit as winter, spring, or facultative types.

Global Significance

Barley (Hordeum vulgare L.) is one of the most widely produced cereal crops worldwide, with over 145 million metric tons produced in 2023, and is ranked as the fourth most-produced cereal after rice, wheat, and maize. Cultivated barley is mainly grown for animal feed, especially for pigs, for malting and brewing in the manufacture of beer, and distilling in whisky manufacture.

Parts Used and Common Preparations

For therapeutic and medicinal purposes, barley can be consumed as juices or powder made from the young leaves of the plant, but also as barley water obtained from barley grains. Pearled barley is eaten in soups and stews in the UK and the Far and Middle East; barley is also used in bread (as flour) and ground as porridge in some countries.

Common preparations documented in the literature include:

• Whole (hulled) barley: The least processed form, retaining the bran, germ, and endosperm; highest in fiber and phytonutrients.
• Pearl (pearled) barley: Pearl barley has been processed to remove its outer husk and sometimes its bran layer.
• Barley flour: The flour derived from barley grains plays a crucial role in numerous processed food items, contributing to their taste and nutritional value.
• Barley grass (young leaf) powder or juice: Derived from young green shoots harvested before the grain forms.
• Barley water: A preparation historically used for medicinal purposes, made by boiling whole or pearl barley in water.
• Germinated barley foodstuff (GBF): A preparation used in some clinical research, produced by germinating barley grains.
• Barley β-glucan concentrate: A concentrated mixed-linkage cereal beta-glucan ingredient (a viscosity-forming soluble fiber) derived from barley and used in functional foods and dietary supplements.
• Malt: Germinated and dried barley used in brewing and as a flavoring agent.

2. Traditional and Historical Use

Origins and Early Cultivation

According to archaeological findings, barley was first domesticated in the Fertile Crescent about 10,000 years ago from its wild relative Hordeum spontaneum. Since then, it has been moulded by the hands of many cultures and has been carried to different parts of the world. Its medicinal and food use dates back to 7000 BC. Crop reports on barley date back to 2440 BC, and the Chinese were cultivating barley circa 2000 BC.

Ancient Mesopotamia and the Near East

In the land between the Tigris and Euphrates, barley was king. Mesopotamian healers used barley in various forms to treat a wide range of conditions. They created barley pastes for skin ailments, barley broths for digestive issues, and even barley-based alcoholic beverages believed to have medicinal properties. These ancient practitioners understood the importance of diet in maintaining health, and barley was often prescribed as both food and medicine.

Ancient Greece and Rome

Barley is one of the first domesticated grains; the use of barley for food and medicinal purposes dates to antiquity. The ancient Greeks used the mucilage derived from the cereal (known as ptisane) to treat gastrointestinal (GI) inflammation. Gladiators ate barley for strength and stamina, and the Roman physician Gaius Plinius Secundus (known as Pliny the Elder, AD 23–79) used barley as part of a ritualized cure for boils.

Ancient Egypt

Egyptians brewed barley into beverages, used barley grass in poultices, and offered it to the gods for health and protection. Since biblical times, ancient Asian and Middle Eastern cultures reportedly included young wheat and barley grass plants in their diets.

Ayurvedic and South Asian Traditions

In Ayurveda, barley ("Yava") was used to balance digestion and purify the blood. Barley is one of the most ancient cereals that has been used for food and medicinal purposes since the distant past. Historically, Egyptian, Greek, Roman, Chinese, and Indian civilizations have relied heavily on barley as a nutritious food source as well as a therapeutic agent for various ailments. Its health-protective activity is endorsed by many religions and traditional medicines including the Unani system of medicine.

Unani Medicine

Barley, which is referred to as 'Jao' in the Unani system of medicine, has a long history of utilization as a food and medicine. In Unani medicine, barley is prescribed for many health conditions such as anti-inflammatory, wound-healing, anti-diabetic, anti-obesity, etc. In Unani medicine, barley is considered cooling, nutritive, and humoral balancing, with applications in managing excess Dam (blood) and Safra (yellow bile), promoting digestion, and supporting overall vitality.

Traditional Chinese Medicine

In Traditional Chinese Medicine, barley sprouts were prescribed for "clearing heat" and supporting liver health.

Prophetic and Islamic Medicine

In Prophetic medicine, barley is prescribed to be consumed as talbina (porridge made from barley flour, milk and honey) to remove weakness of the heart.

Historical Use in Skin, Liver, and Blood Disorders

Historically, the plant species was used in the treatment of skin, liver, blood, and GI disorders. In 1940, it was explained how the vitamins, minerals, and protein in the cereal grasses are essential to animals and humans.

3. Key Constituents and Active Compounds

Macronutrient Composition

Barley consists of complex carbohydrates (80%), proteins (11.5–14.2%), lipids (4.7–6.8%), β-glucans (3.7–7.7%), and ash (1.8–2.4%). From a nutritional point of view, barley is rich in starch, protein, dietary fiber and minerals, as well as antioxidant compounds and vitamins.

β-Glucan (Beta-Glucan)

The most extensively studied and clinically important constituent of barley is its soluble fiber, β-glucan. β-glucan is particularly abundant in the cell walls of the endosperm of barley and oats, making up around 70%, and is also present in the aleurone layer. Barley β-glucan consists of mixed-linkage β-D-glucan with β-1,3 and β-1,4 glucoside bonds in a 3:7 ratio with a content of 3.0–6.9%, of which 38–69% is water soluble. Barley contains around 5–11% β-glucan by weight.

Of all cereal crops that contain β-glucan, barley has the highest reported content.

Phenolic Compounds and Polyphenols

Beyond its other nutrients, barley boasts a good reservoir of phenolic compounds (1.2–2.9 mg/g GAE). Barley whole grains and its outer bran layer are rich in functional ingredients, especially fiber, phenolic acids, flavonoids, phytosterols, alkylresorcinols, benzoxazinoids, lignans, tocol, and folate; 64 compounds in barley were identified as 27 anthocyanins, 9 flavanols, 9 flavone glycosides, and 19 phenolic acids and aldehydes.

Vitamins

Barley contains several vitamins, including thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, and folate. It also contains tocols (a vitamin E family) among its functional compounds.

Phytosterols, Tocols, and Lignans

The phytonutrients in whole-grain barley include flavonoids, phenolic acids, folate, phytosterols, tocols, and lignans. Some functional components of barley associated with cardiovascular health include polyphenols, phytosterols, lignans, tocols, and folate.

Proteins and Amino Acids

Barley contains essential amino acids among its functional compounds. Barley's storage proteins are called hordeins, which are the gluten proteins specific to this grain (discussed further in the safety section).

Resistant Starch and Arabinoxylan

Major anticancer elements in barley include β-glucan, phenolics, arabinoxylan, phytosterols, lignan, and resistant starch. These additional dietary fibers contribute to the grain's overall digestive and metabolic effects.

4. Mechanisms of Action

Cholesterol-Lowering Mechanism

Beta-glucan is a viscous soluble fiber found in oats and barley that can interfere with cholesterol absorption and bile acid recycling in the digestive tract. The result is often a modest reduction in LDL cholesterol, sometimes called "bad" cholesterol. The widely accepted mechanism is that β-glucan, when ingested, forms a viscous gel in the intestine that impedes the reabsorption of bile acids. The liver then draws on circulating cholesterol to synthesize new bile acids, thereby lowering serum cholesterol.

Glycemic Modulation Mechanism

The widely hypothesized mechanism through which cereal β-glucan reduces post-prandial blood glucose is its ability to form viscous solutions. It is purported that β-glucan increases luminal viscosity, thereby decreasing the interaction between digestive enzymes and their substrates as well as simple sugars and intestinal nutrient transport proteins. More specifically, research has shown that the mechanism by which β-glucan from barley attenuates post-prandial glycemic response is via alteration of α-glucosidase, GLUT2, and SGLT1 activity, but not amylolysis of starch.

Much evidence has shown that the viscosity of β-glucans should be the primary factor responsible for lowering glycemic, insulinemic, and LDL-cholesterol levels. Critically, the molecular weight (MW) of the β-glucan polymer influences viscosity and, consequently, physiological effect.

Gut Microbiota Modulation

Since humans lack enzymes for the digestion of β-glucan and other dietary fibers, the majority of these compounds are fermented in the lower GI tract via carbohydrate active enzymes (CAZymes) produced by gut microbiota, potentially resulting in compositional and functional shifts in the microbiome. Gut microbiota contribute to host nutrition and energy metabolism via production of short chain fatty acids, amino acids, and vitamins. The microbial-derived metabolites can be distributed well beyond the GI tract and influence the physiology of the host, enabling this complex network of microorganisms to act as a virtual endocrine organ, playing an important role in host health and disease status.

Satiety Hormones

Barley β-glucan has been found to lead to increased levels of plasma PYY and GLP-1. PYY and GLP-1 suppress the appetite, and GLP-1 promotes glucose-dependent insulin secretion.

Anti-inflammatory and Antioxidant Mechanisms

Oxidative stress and inflammation are two important factors of atherosclerosis, and polysaccharide extracts with antioxidation and anti-inflammation of hulless barley prevent cardiovascular diseases. Barley with preventive inflammatory and cardiovascular disease activity has exhibited activity against all human platelet agonists and has inhibited both cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health and Cholesterol Reduction

Regulatory Status: The FDA has approved the health claim: "consumption of 3g or more per day of beta-glucan soluble fibre from either whole oats or barley, or a combination of whole oats and barley, as part of a low saturated fat and cholesterol diet, may reduce the risk of heart disease." In 2011 and 2012, the EFSA also approved a claim for 3g daily of beta-glucan from barley or oats to lower blood cholesterol.

Meta-analyses: Eleven eligible randomized clinical trials published from 1989 to 2008 were identified. Weighted mean effect sizes were calculated using a random effect model. Overall, barley and β-glucan isolated from barley lowered total and low-density lipoprotein (LDL) cholesterol concentrations by 0.30 mmol/L (95% CI: −0.39 to −0.21, P<0.00001) and 0.27 mmol/L (95% CI: −0.34 to −0.20, P<0.00001), respectively, compared with control.

Further meta-analyses of randomised controlled trials have consistently demonstrated that around 3g of beta-glucan a day reduces total cholesterol by 0.25–0.66 mmol/L and LDL cholesterol by 0.24–0.6 mmol/L.

Dose range studied: Daily beta-glucan doses ranged from 1.2 to 10 g/day in total cholesterol studies.

Basis for FDA petition: The FDA-approved barley health claim was based on a petition that included 39 animal model studies and 11 human clinical trials. Since then, more studies have been published, but with few exceptions, clinical data continue to demonstrate that the consumption of barley products is effective for lowering total and LDL cholesterol.

Limitations and Inconsistencies: The results of clinical studies have been mixed, but largely demonstrate positive findings. Reductions in LDL and total cholesterol have been shown in a number of trials conducted in hypercholesterolemic patients. However, a number of studies have been unable to demonstrate changes in lipid profiles. One reason proposed for the negative findings is the molecular weight of the beta-glucan used in the trial, with positive results being attributed to higher molecular weight glucan content.

Specific trial example (negative finding): A randomized crossover trial was unable to provide evidence of a significant improvement in CVD risk or type 2 diabetes risk in a group of mildly hypercholesterolemic, middle-aged men fed a highly enriched form of barley-derived β-glucan as part of a typical 38% fat diet. Total cholesterol decreased by only 1.3% and LDL cholesterol by 3.8% over the 4-week intervention period, indicating a very modest improvement, if any. This trial involved eighteen mildly hyperlipidemic men administered 8.1–11.9 g beta-glucan/day (scaled to body weight).

Overall evidence strength: Moderate to strong for LDL and total cholesterol reduction, supported by multiple RCTs and meta-analyses, and recognized by major regulatory agencies. Effects are modest in absolute terms and depend significantly on β-glucan molecular weight and solubility.

5.2 Blood Glucose Regulation and Glycemic Control

Regulatory Status: Extensive scientific evidence has demonstrated the health benefits of β-glucans from barley and oats in lowering cholesterol and regulating blood glucose, leading both the U.S. FDA and the EFSA to approve health claims for their role in reducing cardiovascular disease and controlling postprandial glycemic responses.

EFSA dose threshold: EFSA approved a health claim for barley and oat β-glucan and post-prandial blood glucose when the dose is ≥ 4g β-glucan for every 30g available carbohydrate. However, the EFSA Panel considered that the human intervention studies did not consistently show a significant effect of beta-glucans from oats or barley on postprandial glucose iAUC at doses between 2 and <4g BG/30g avCHO, and that dose–response data suggest a lowest effective dose above the 2g/30g avCHO level.

Randomized clinical trial data: In a randomized, controlled, crossover clinical trial evaluating the effects of sweetened and unsweetened high β-glucan whole grain barley on postprandial blood glucose response in normoglycemic human subjects, in both sweetened and unsweetened conditions, higher β-glucan content was associated with lower blood glucose peak response and incremental area under the curve (iAUC). By attenuating postprandial glycemic response, high β-glucan whole grain barley foods could play a role in helping to control blood glucose.

Appetite and insulin effects: Barley dietary fiber (BDF) consumption significantly delayed the postprandial increase in blood glucose compared with placebo, reduced insulin secretion, and slightly increased glucagon and triglycerides. BDF also lowered hunger and increased satiety, with associated increases in ghrelin and PYY levels. BDF consumption, particularly from β-glucan-rich barley, may improve postprandial glycemic control and suppress appetite, making it a promising dietary intervention for managing metabolic conditions such as diabetes.

Overall evidence strength: Moderate. Evidence is consistent for acute postprandial glycemic reduction. Longer-term effects in people with established diabetes remain an area of ongoing investigation, and the EFSA notes that evidence is inconsistent below the 4g β-glucan/30g carbohydrate threshold.

5.3 Gut Health and Microbiome

The role of microbiota in maintaining good health is now clearly established, and evidence suggests that the consumption of oats and barley can support the growth and maintenance of gut microorganisms.

Microbiota and cholesterol response: When participants were grouped according to their response to β-glucans at the cholesterol level, the pre-intervention gut microbiota composition showed higher abundance of health-associated Bifidobacterium spp. and Akkermansia muciniphila within the cholesterol-responsive group, concluding that barley β-glucans' metabolic response is possibly dependent on individual gut microbiota composition.

Molecular weight matters: The main finding of one controlled feeding study was that gut microbiota were modulated in response to barley β-glucan consumption in a molecular weight (MW)-dependent manner, and that shifts in gut microbiota were correlated with reduced CVD risk markers.

Short-chain fatty acids: Highland barley β-glucan could enrich microbial diversity, increase the abundance of beneficial bacteria, and inhibit pathogenic bacteria. In addition, it increased the content of short-chain fatty acids and decreased fermentation broth pH. Metabolomics analyses showed that it also increased the content of beneficial metabolites such as taurine and affected amino acid metabolism. Note that this study was conducted using an in-vitro fermentation model, not in humans directly.

Whole grain and inflammation: Whole grain oats and barley, rich in nutrients, dietary fiber, phytochemical compounds, and a range of (poly)phenols, may have the potential to act in an anti-inflammatory manner especially in metabolically at-risk populations. These effects seem to be intricately linked to alterations in gut microbiota composition.

Overall evidence strength: Emerging and promising. Most human data come from small trials or are inferred from mechanistic and animal studies. The finding that individual microbiome composition influences response to barley β-glucan adds complexity. More large-scale human RCTs are needed.

5.4 Body Weight and Satiety

Satiety evidence: Ten satiety trials were evaluated and provide evidence that whole oats, barley, and rye can increase satiety, whereas the evidence for whole wheat and maize is not compelling.

Weight management RCT: After 6 weeks, between-group comparisons in a randomized trial revealed significant differences favoring the barley group in body weight (barley: −0.33 kg vs. corn: +0.85 kg; difference: −1.18 kg, p = 0.027), BMI (difference: −0.17 kg/m², p = 0.014), and glycated albumin (difference: −0.87%, p = 0.032). Within-group analyses showed that the barley group exhibited significant reductions in percent body fat (−1.03%, p = 0.004), waist circumference (−3.64 cm, p = 0.003), waist-to-hip ratio (−0.02, p = 0.012), glycated albumin (−0.78%, p = 0.029), and LDL cholesterol (−10.57 mg/dL, p = 0.033).

Mechanism underpinning satiety: β-glucan has shown physiological benefits including weight management via increasing satiety. The proposed mechanism involves viscosity-mediated slowing of gastric emptying and induction of satiety hormones including PYY and GLP-1.

Overall evidence strength: Preliminary to moderate. Satiety effects are better documented than long-term weight loss outcomes. The number of large, long-duration RCTs specifically examining barley's role in sustained weight management remains limited.

5.5 Anti-inflammatory Effects

Regular consumption of whole grain barley and its hydroalcoholic extract is associated with reduction of risk of chronic diseases (diabetes, cancer, obesity, cardiovascular disease, etc.), based on phytochemicals including β-glucan, phenolic acids, flavonoids, lignans, tocols, phytosterols, and folate. Whole grain oats and barley, rich in nutrients, dietary fiber, phytochemical compounds, and a range of (poly)phenols, may have the potential to act in an anti-inflammatory manner especially in metabolically at-risk populations.

Overall evidence strength: Preliminary. Most anti-inflammatory evidence comes from in vitro studies, animal models, and mechanistic inference. Robust human RCT data specifically targeting inflammatory biomarkers with barley interventions are limited.

5.6 Antioxidant Effects

Barley is also rich in phenolic compounds, flavonoids, tocols, lignans, and phytosterols, which provide antioxidant, anti-inflammatory, cardioprotective, and anticancer effects. These phytochemicals are helpful due to their cholesterol-reducing abilities, their antiproliferative and antioxidant activities, and their effectiveness in reducing the risk of certain disorders.

Overall evidence strength: Mostly preclinical and mechanistic. Human bioavailability of barley phytochemicals has been examined in small crossover trials, but clinical outcomes from antioxidant activity specifically attributable to barley remain insufficiently demonstrated.

5.7 Inflammatory Bowel Disease (IBD)

Germinated barley foodstuff (GBF) has been investigated in the context of ulcerative colitis. Clinical research referenced in pharmacological databases includes a multicenter open control trial of treatment of ulcerative colitis by feeding with germinated barley foodstuff. Additionally, a randomized controlled trial examined a fermented barley-based preparation (Profermin) in patients with active ulcerative colitis. These trials are referenced in medical databases but represent early-stage, limited evidence requiring replication in larger controlled studies.

Overall evidence strength: Preliminary. GBF has shown signals of benefit in small or open-label IBD trials but has not been tested in large, phase III-level RCTs.

6. Body Systems and Health Areas Associated with Barley

• Cardiovascular system: LDL cholesterol reduction, total cholesterol reduction, via β-glucan bile acid binding; supported by FDA and EFSA health claims.
• Metabolic/Endocrine system: Postprandial blood glucose attenuation, insulin modulation; EFSA-approved health claim for glycemic response.
• Gastrointestinal system: Prebiotic fiber effects, gut microbiome modulation, short-chain fatty acid production, bowel regularity; investigated in IBD.
• Adipose/Weight regulation: Satiety promotion via viscosity and gut hormone induction; limited weight management RCT data.
• Immune system: β-glucan intake has been associated with strengthened immune responses.
• Antioxidant/Cellular protection: Phenolic compounds, tocols, and flavonoids contribute to antioxidant capacity; clinical relevance in humans requires further study.

7. Dosage Forms and Dosages Reported in Studies

Dosage data are drawn directly from the cited clinical literature and regulatory assessments:

• β-glucan for cholesterol reduction (FDA/EFSA-recognized dose): The FDA endorses a daily intake of 3g of β-glucans from oat or barley sources to reduce the risk of coronary heart disease.
• β-glucan for postprandial blood glucose (EFSA-approved dose): EFSA approved a health claim for barley and oat β-glucan and post-prandial blood glucose when the dose is ≥4g β-glucan for every 30g available carbohydrate.
• Dose range in clinical cholesterol trials: Daily beta-glucan doses ranged from 1.2 to 10 g/day in total cholesterol studies.
• Crossover trial (mildly hypercholesterolemic men): Eighteen mildly hyperlipidemic men received 8.1–11.9g beta-glucan/day (scaled to body weight) in a single-blind, 2 × 4-week crossover trial.
• Specific cholesterol trial (Behall et al.): In one study, 7 men and 18 women were given test diets providing 0, 3, or 6g/day of barley β-glucan. Following both the 3g/day and 6g/day diet periods, serum total cholesterol was reduced 5 and 6%, respectively, and LDL cholesterol reduced by 10%.
• Glycemic response crossover RCT: Participants consumed an unsweetened preload condition (n=16): white glutinous rice (0g β-glucan), low β-glucan barley (~4g), medium β-glucan barley (~5g), or high β-glucan barley (~6g).
• Glycemic dose study: One study tested three doses (2, 4, and 6g of β-glucan per 30g of available carbohydrate), all of which were effective in reducing post-prandial glycemic response by more than 20%.
• Recommended daily dose range: The recommended daily dose in adult individuals is between 3 and 4g of β-glucans daily.

Barley β-glucan is delivered in whole grain form (whole barley, pearl barley, barley flakes, barley flour) and as concentrated β-glucan supplements or enriched food products. Processing affects molecular weight and solubility of β-glucan, which in turn affects physiological efficacy.

8. Safety Considerations and Interactions

Celiac Disease and Gluten (Hordein) Toxicity

Celiac disease is an autoimmune disorder triggered by an immune-mediated response of the small intestine to dietary gluten, which is a protein found in wheat, barley, and rye. Barley, a vital cereal crop worldwide, is hindered by hordeins, gluten proteins triggering adverse reactions in those with celiac disease (CeD) and non-celiac gluten sensitivity (NCGS).

Damage to the small intestine in celiac disease is evidenced by villous atrophy, crypt hyperplasia, and infiltration of the lamina propria by immune cells, which in turn leads to malabsorption of essential nutrients, including micronutrients, fat-soluble vitamins, iron, vitamin B12, and folate.

Clinical studies concluded that barley is harmful to patients with celiac disease. In food manufacturing, barley is often used in ways that do not resemble whole grain form, such as malt flavoring, syrups, or extracts. These forms can still contain gluten and are problematic for people with celiac disease or non-celiac gluten sensitivity.

Recent barley breeding advancements focus on creating varieties with reduced hordein content. Researchers have developed ultra-low gluten barley mutants via targeted genetic modifications, showing significantly decreased hordein levels, potentially safe for CeD and NCGS individuals. However, some mutants carry undesirable traits, which are addressed through further breeding and new genomic techniques.

Gastrointestinal Side Effects

High fiber intake from barley, particularly large amounts of β-glucan, can cause gastrointestinal discomfort including bloating, flatulence, and increased bowel movements, especially when introduced abruptly into the diet. These effects are typical of high soluble-fiber foods and are not unique to barley.

Drug Interactions: Absorption Interference

Taking barley along with medicine taken by mouth can decrease the effectiveness of the medication. To prevent this interaction, barley should be taken at least 1 hour after medications taken by mouth. This interaction is attributable to the viscous fiber content of barley, which can slow gastric emptying and alter the absorption kinetics of co-ingested medications.

Blood Glucose-Lowering Medications

Given barley's established ability to attenuate postprandial blood glucose, its concurrent use with antidiabetic medications (e.g., insulin, sulfonylureas, or other glucose-lowering agents) could theoretically produce additive blood glucose-lowering effects. Clinical monitoring of blood glucose levels is prudent in these circumstances, though specific documented cases of clinically significant hypoglycemia from barley–drug interactions have not been established in the reviewed literature.

Allergy

Barley can cause allergic reactions in susceptible individuals, including those with cereal grain allergies. The grain contains multiple proteins with allergenic potential, distinct from the hordein/gluten sensitivity described above.

Pregnancy and Special Populations

Barley consumed as a whole food at normal dietary amounts is considered a safe staple food. The safety of concentrated barley extracts or high-dose β-glucan supplements in pregnancy has not been adequately studied in clinical trials reviewed in this article.

Interference with Drug Immunoassays

Barley contains the alkaloid hordenine, which has been documented to interfere with certain immunoassay and thin layer chromatography methods used for drug screening in urine. This is a recognized analytical interference, not a pharmacological drug interaction.

9. Summary of Evidence Strength

• Cholesterol reduction (β-glucan, ≥3g/day): Strong. Supported by multiple RCTs, meta-analyses, and regulatory health claim approvals (FDA, EFSA).
• Postprandial blood glucose attenuation (β-glucan, ≥4g/30g carbohydrate): Moderate to strong for acute effects; evidence for long-term glycemic control in diabetic patients is less conclusive.
• Gut microbiome modulation: Preliminary. Mechanistically plausible and supported by in vitro and limited human data; large-scale RCTs lacking.
• Satiety and weight management: Moderate for satiety; preliminary for long-term weight outcomes.
• Anti-inflammatory effects: Preliminary. Largely based on preclinical data and indirect evidence from whole grain studies.
• IBD (germinated barley foodstuff): Preliminary. Small or open-label trials only.

References

• Unraveling the Hidden Potential of Barley (Hordeum vulgare): An Important Review — PMC/PubMed (2024)
• Unraveling the Hidden Potential of Barley (Hordeum vulgare): An Important Review — MDPI Plants (2024)
• Review on Structure, Functional and Nutritional Composition of Barley (Hordeum vulgare) — Auctores Online (2021)
• Nutritional Composition and Phenolic Compounds in Barley: A Review of the Effects of Drying, Storage, and Processing — ScienceDirect (2025)
• Beta-glucan from Barley and its Lipid-Lowering Capacity: A Meta-analysis of Randomized, Controlled Trials — PubMed (AbuMweis et al., 2010)
• Beta-glucan from Barley and its Lipid-Lowering Capacity: DARE Quality-assessed Review — NCBI Bookshelf
• A Systematic Review and Meta-analysis of RCTs of the Effect of Barley β-glucan on LDL-C, Non-HDL-C and ApoB — PubMed (Ho et al., 2016)
• Randomized Controlled Crossover Study of Highly β-glucan–Enriched Barley on CVD Risk Factors — PMC (Keogh et al., 2003)
• High β-Glucan Whole Grain Barley Reduces Postprandial Glycemic Response in Healthy Adults — PMC (2025)
• Beta-Glucan From Barley Attenuates Post-prandial Glycemic Response by Inhibiting Glucose Transporters — PMC (2021)
• High Molecular Weight Barley β-Glucan Alters Gut Microbiota Toward Reduced Cardiovascular Disease Risk — PMC (2016)
• Effect of Barley and Oat Consumption on Immune System, Inflammation and Gut Microbiota: A Systematic Review of RCTs — PMC (2024)
• Barley β-glucan Improves Metabolic Condition via Short-chain Fatty Acids Produced by Gut Microbial Fermentation — PMC (2018)
• Effects of Highland Barley β-glucan on Gut Microbiota Composition and Metabolism in In Vitro Fermentation — PMC (2025)
• Effect of Barley on Postprandial Blood Glucose Response and Appetite in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Trial — PMC (2024)
• Barley-Based Cereals Enhance Metabolic Health and Satiety in Overweight Korean Adults: A Randomized Trial — PMC (2025)
• Does Whole Grain Consumption Alter Gut Microbiota and Satiety? — PMC (2016)
• EFSA Scientific Opinion on Barley Beta-glucans and Lowering of Blood Cholesterol — PMC/EFSA
• EFSA Opinion: Beta-glucans from Oats or Barley and Reduction of Postprandial Glycaemic Responses — PMC (2025)
• Issues Surrounding Health Claims for Barley — The Journal of Nutrition (2008)
• Molecular Mechanism of Functional Ingredients in Barley to Combat Human Chronic Diseases — PMC (2020)
• Preventive and Therapeutic Role of Functional Ingredients of Barley Grass for Chronic Diseases — PMC (2018)
• Phytochemical Pharmacokinetics and Bioactivity of Oat and Barley Flour: A Randomized Crossover Trial — PMC (2017)
• Oats and Barley Toxicity in Coeliac Patients — PMC
• Celiac Disease — StatPearls, NCBI Bookshelf, NIH
• Barley's Gluten Challenge: A Path to Hordein-Free Food and Malt — PubMed (2024)
• Importance of Barley (Hordeum vulgare Linn.) as Food and Medicine from Past to Present — Phytopharmacology Journal
• Barley Uses, Benefits & Dosage — Drugs.com
• Barley Grass Uses, Benefits & Side Effects — Drugs.com
• A Critical Review on the Impacts of β-glucans on Gut Microbiota and Human Health — ScienceDirect (2025)
• The Chemical Composition of Barley Grain (Hordeum vulgare L.) Landraces from the Canary Islands — PubMed (2020)
• Changes in the Nutrient Composition of Barley Grain and Morphological Fractions of Sprouts — PMC (2021)
• Oats and Barley — HEART UK (Cholesterol Charity)